Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

Matching articles

Showing 1–12 of 77 articles · Interpret the evidence

Clear search and filters

  • Interpret the evidence

    Why the Duchenne trial ended early

    ACE-031 is an investigational fusion protein that captures myostatin and related signaling proteins through a soluble piece of activin receptor type IIB. An older human study, first published online in 2016, asked how boys with Duchenne muscular dystrophy tolerated that approach.

    ACE-0312 sources (2016, 2026)

  • Interpret the evidence

    Why bigger muscles did not settle the FSHD trial

    ACE-083 is an investigational fusion protein based on follistatin. It was engineered to sequester myostatin, activins and other signals around a targeted muscle.

    ACE-0831 source (2022)

  • Interpret the evidence

    What a rabbit knee study can tell us about AOD-9604

    AOD-9604 is a modified peptide from the tail of human growth hormone. In an older animal experiment, researchers tested whether it changed measures of knee cartilage damage when studied alone or with hyaluronic acid. Hyaluronic acid is a large sugar-based molecule found in joint fluid.

    AOD-96042 sources (2015, 2024)

  • Interpret the evidence

    How the diabetes trial separated symptoms from glucose markers

    ARA-290 is an experimental 11-amino-acid peptide designed from erythropoietin to study tissue responses without reproducing its red-blood-cell stimulus.

    ARA-2902 sources (2008, 2015)

  • Interpret the evidence

    What three dental nerve cases can tell us about a mixture

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 can refer to a synthetic acetylated seven-amino-acid fragment of thymosin beta-4, although an experimental report needs to identify what its authors used.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Interpret the evidence

    What the four groups in a rat tendon study could compare

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 commonly denotes an acetylated seven-amino-acid fragment of thymosin beta-4. In July 2026, investigators used BPC-157 and a reagent they called TB-500 to ask whether giving them together changed healing after Achilles tendon repair in rats.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Interpret the evidence

    Why collagen appearance and tendon strength can tell different stories

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 generally refers to an acetylated seven-amino-acid fragment of thymosin beta-4. In a 2026 study of rat Achilles tendons, the investigators used BPC-157 and a supplier reagent labeled TB-500.

    BPC-157 / TB-5002 sources (2012, 2026)

  • Interpret the evidence

    What an older knee chart review actually compared

    BPC-157 is a synthetic 15-amino-acid peptide. TB-500 usually refers to an acetylated seven-amino-acid fragment of thymosin beta-4. An older 2021 knee report described BPC-157 together with a substance called TB4.

    BPC-157 / TB-5002 sources (2012, 2021)

  • Interpret the evidence

    Why REIMAGINE 2 compared cagrilintide with semaglutide

    Cagrilintide is an investigational long-acting peptide modeled on amylin. Semaglutide acts on the GLP-1 receptor. REIMAGINE 2 studied the two peptides alone and together in people with type 2 diabetes and overweight or obesity.

    Cagrilintide2 sources (2025, 2026)

  • Interpret the evidence

    What a cagrilintide combination changed in a basal insulin trial

    Cagrilintide is an investigational peptide designed to act like the hormone amylin for longer. In the 2026 REIMAGINE 3 study, researchers asked what changed when the cagrilintide–semaglutide combination, called CagriSema, was added to basal insulin in adults with type 2 diabetes.

    Cagrilintide1 source (2026)

  • Interpret the evidence

    What the Japan and Taiwan CagriSema trial adds to the evidence

    Cagrilintide is a long-acting investigational amylin-based peptide. CagriSema pairs it with the GLP-1 receptor agonist semaglutide. In REDEFINE 5, researchers examined whether the combination produced a different weight change from semaglutide alone in adults studied in Japan and Taiwan.

    Cagrilintide1 source (2026)

  • Interpret the evidence

    What the growth hormone–releasing hormone receptor can tell us

    CJC-1295 No DAC commonly refers to Mod GRF (1–29), a synthetic 29-residue relative of growth hormone–releasing hormone (GHRH) with four substitutions. Its design raises a specific question about how the original hormone engages its receptor.

    CJC-1295 No DAC2 sources (2020, 2024)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)